Skip to ContentSkip to Navigation
How to find us prof. dr. E.M.D. (Ed) Schuuring
University Medical Center Groningen

prof. dr. E.M.D. Schuuring

Professor of Molecular Oncological Pathology
prof. dr. E.M.D. Schuuring
E-mail:
e.schuuring umcg.nl

Onderwijs: bijscholing, nascholing en invited lectures (year/period, institute - evaluation period 2015 - 2019):

  1. “Next-generation pathology: molecular tumor makeup for optimal precision medicine”, Research and Development Day, Novartis, 10 feb 2015
  2. “Genome-wide methylome analysis discovers novel methylation markers for both cervical adenocarcinomas and squamous cell carcinomas”, Eurogin 2015, 4-7 Feb 2015, Sevilla
  3. Organization of an EQA scheme for somatic mutation testing in liquid biopsies”, ESP advisory board meeting, Naples, 10-11 April 2015
  4. Next-generation pathologie in de diagnostiek van longkanker, Voorjaarscongres WIHC 2015 Longpathologie, 20 May 2015, Soestdijk
  5. “Next-generation pathologie in de diagnostiek van longkanker”, HLO Hanze Hogeschool Groningen, 12 June 2015, Groningen (gastcollege)
  6. “Circulating plasma DNA biomarker”, CMI Groningen Meeting “Lung Cancer and Emphysema Biomarkers”, Groningen 30 April 2015
  7. “Nieuwe anti-tumor therapie: ontwikkelingen in de moleculaire pathologie, therapie op maat”, Masterclass voor (oncologie) verpleegkundigen, Amersfoort, 13 april 2015
  8. “De longkankercel, kennis vanuit de medisch pathologische oncologie”, Masterclass voor (oncologie) verpleegkundigen, Groningen, 17 april 2015
  9. “Samenvatting resultaten rondzendingen Moleculaire Pathologie: QCMD HPVDNA EQA Program 2014”. Deelnemersbijeenkomst SKML sectie-Pathologie. Amersfoort. 16 June 2015
  10. “Targeting Molecular Pathways beyond EGFR and ALK”, 4th ETOP Residential Workshop, 20-22 August 2015, Amsterdam
  11. “Next generation sequencing, Hopes and hurdles, What you need to know”, 4th ETOP Residential Workshop, 20-22 August 2015, Amsterdam
  12. “A practical guide to navigating your way to the right test for detecting every ALK”, Novartis Oncology Satelitte Symposium, 27th European Congress of Pathology, Belgrado, 7th September 2015
  13. “De detectie van chromosomale afwijkingen mbv DNA in-situ hybridizatie in de moleculaire diagnostiek”, NVVP-BOP-cursus voor AIOS Pathologie “Moleculaire Pathologie”, 30 sept-1 oct 2015, Arnhem
  14. “Basale moleculaire biologie in onze diagnostiek”, NVVP-BOP-cursus voor AIOS Pathologie “Moleculaire Pathologie”, 30 sept-1 oct 2015, Arnhem
  15. “Personalized Meds from the molecular onco-pathology’s perspective”, FIGON DMD Symposium, “From Protocol towards Personalized Tailored Therapy”, Ede, 6 October 2015 [http://doczz.nl/doc/527110/figon-2015-schuuring]
  16. “ALK IHC vs FISH (Quality Assurance)”, Netherlands Lung Advisory Board Meeting, Pfizer, “NSCLC, diagnostics, treatment and new developments”, 22 Oct 2015, Utrecht
  17. “Vernieuwing en diagnostiek bij NSCLC”, 8ste avondsymposium “Nieuwe ontwikkelingen in de behandeling van NSCLC”, Groningen, 28 October 2015
  18. “Laatste moleculaire diagnostische ontwikkelingen tav blood-based DNA testing en mogelijke implicaties van liquid biopsie in de dagelijkse praktijk”, Amgen Adviesraad Molecular aspects of colorectal cancer, 10 November 2015, Park Plaza, Utrecht
  19. “Molecular Diagnostics of Lung Cancer: Optimizing access to personalized cancer therapy in The Netherlands; from tissue to therapy (2015-2020)”, 11th congress on Lung Cancer, 27 November 2015, Barcelona
  20. “Targeted therapie voor longcarcinoom, het belang van moleculaire diagnostiek”. 5de dag van het NVPF Curriculum medicatiebeoordeling “Longkanker en borstkanker”, 15 december 2015, Veenendaal
  21. Behandelkeuze voor targeted-therapie aan de hand van mutatie-analyse op cel-vrij plasma DNA, 10de bijeenkomst Werkgroep “Moleculaire Diagnostiek in de Pathologie”, 15 Januari 2016, Utrecht [https://pathology.nl/wp-content/uploads/PDF/publicaties/presentaties/moleculaire_ diagnostiek/2016-01-15_Mol_Dag_Schuuring.pdf]
  22. “Personalized Meds from the molecular onco-pathology’s perspective”, Oncologie-bespreking UMCG, 26 Feb 2016
  23. “Next-generation pathologie in de diagnostiek van longkanker”, HLO Van Hal Leeuwarden, June 2016, Groningen (gastcollege)
  24. “Nieuwe anti-tumor therapie: ontwikkelingen in de moleculaire pathologie, therapie op maat”, Masterclass voor (oncologie) verpleegkundigen, Amersfoort, 10 April 2016 [http://docplayer.nl/17364341-10-4-2016-ontwikkelingen-in-de-moleculaire-pathologie-ed-schuuring-therapie-op-maat-classical-pathology.html]
  25. “BRAF-V600 mutatie sneldiagnostiek”, Biocartis Symposium: “High precisions diagnostics for personalized medicine”, Week van de Pathologie, Zeist, 12 April 2016
  26. “Genome-wide methylome analysis discovers methylation markers for both adeno- and squamous cell carcinomas”, Eurogin, 15-18 June 2016, Salzburg
  27. “FISH replacement by fusion detection with NGS” , 1st Annual Genomics-in-Oncology Summit, Illumina, 24 May 2016, Barcelona, Spain
  28. “Monitoring GIST patients by detection of blood derived ctDNA”, Annual ECP meeting 2016, Two day Symposium for Molecular Biologists involved in Molecular Diagnostic Pathology and Research, Session: “Are liquid biopsies the future ?” 26-27 Sept 2016, Köln
  29. “Optimizing access of all patients to personalized cancer therapy”, Biocartis Webinar: “Lowering the Barriers for Practical Implementation of High Precision Medicine”, 3 Oct 2016 Biocartis
  30. “Predictive testing and monitoring treatment response in cancer patients by detection of circulating tumor DNA in cell free plasma”, Annual QCMD meeting 2016, Stirling, 5-6th October 2016
  31. “Basis van de verandering van het bevolkingsonderzoek baarmoederhalskanker (BVO): wie, hoe waarop gaan we testen ?” Targon bijeenkomst 7 nov 2016
  32. “Basis van de verandering van het bevolkingsonderzoek baarmoederhalskanker (BVO): wie, hoe waarop gaan we testen ?” Regionaal Microbiologisch infectiologisch symposium (REMIS+),10 october 2016, UMCG, Groningen
  33. “Vernieuwing en diagnostiek bij NSCLC”, 9de avondsymposium “Nieuwe ontwikkelingen in de behandeling van NSCLC”, Groningen, 9 nov 2016 [www.moloncopath.nl]
  34. “Organisatie van liquid biopsy diagnostiek in Nederland: wie gaat het doen ?” Discussiepanel, Novemberdagen van de Pathologie, “Diagnostics to the next level”,18 november 2016, Amersfoort
  35. “Wat is er nieuw onder de zon ? Landelijke afstemming m.b.t. gebruik predictieve markers, verslaglegging, kennis transfer advies over therapiekeuze, bloed versus biopt”. Novemberdagen van de Pathologie, “Diagnostics to the next level”,17 november 2016, Amersfoort
  36. “Plasma-testing”, Netherlands Lung Advisory Board Meeting, Pfizer, “NSCLC, diagnostics, treatment and new developments”, 8 dec 2016, Utrecht
  37. “Moleculaire diagnostiek bij NSCLC”, Werkgroep Oncologie, Friesland, 6 december 2016
  38. “Moleculaire Oncologie in Friesland, Routine moleculaire diagnostiek, PATH-studie en CPTC/HMF”, FROHON vergadering, Sneek, Friesland, 24 januari 2017
  39. ”Selectie van patiënten en geschikte therapiekeuze, regionale expert-functie, Werkbezoek dhr Rutten (2de kamerlid), overleg dd 27-01-2017, Groningen
  40. “Predictive testing and monitoring treatment response in cancer patients by detection of circulating tumor DNA in cell free plasma Pathologie”, PA Friesland stafoverleg, Leeuwarden, 11 Mei 2017
  41. “Gevolgen van PATH project voor NSCLC”, 10de avondsymposium “Nieuwe ontwikkelingen in de behandeling van NSCLC: hoe tillen we Moleculaire Diagnostiek NSCLC naar hoger plan”, Groningen, 1 Nov 2017 [www.moloncopath.nl; umcg.nl/SiteCollectionDocuments/UMCG/Afdelingen/ Pathologie_Medische_Biologie/moleculaire%20diagnostiek/10e%20avondsymposium/presentatie-schuuring.pdf]
  42. “De detectie van chromosomale afwijkingen mbv DNA in-situ hybridizatie in de moleculaire diagnostiek”, NVVP-BOP-cursus voor AIOS Pathologie “Moleculaire Pathologie”, 15-16 Maart 2017, Papendaal, Arnhem
  43. “Historisch perspectief van de Moleculaire Pathologie”, NVVP-BOP-cursus voor AIOS Pathologie “Moleculaire Pathologie”, 15-16 Maart 2017, Papendaal, Arnhem
  44. “Predictive testing and monitoring treatment response in cancer patients by detection of circulating tumor DNA in cell free plasma: The UMCG experience” Cancer ID ctDNA meeting, Wuppertal, 16th May 2017
  45. “Immunotherapie en de rol van cfDNA” tijdens de “Eerste Nederlandse cfDNA dag” (NVVP, CMBD, NVKC), 31 mei 2017, Utrecht [www.cfdna.nl/]
  46. “Pre-analytische aspecten: welke pittfals te vermijden” tijdens de “Eerste Nederlandse cfDNA dag” (NVVP, CMBD, NVKC), 31 mei 2017, Utrecht [www.cfdna.nl/]
  47. “Inventarisatie pre-analytische werkwijzen en standaardisatie van ctDNA in Nederland” tijdens de “Eerste Nederlandse cfDNA dag” (NVVP, CMBD, NVKC), 31 mei 2017, Utrecht [www.cfdna.nl/]
  48. “Biomarkers” tijdens “Chicago aan de Wal”, Roche ism Jaap uitgeverij tijdens ASCO, 4th June 2018, Chicago (invited TV-debat)
  49. “Lung cancer: beyond EGFR and ALK” 8th Belgian Week of Pathology Ghent, 19-21 October 2017, Ghent
  50. “Nieuwe anti-tumor therapie: ontwikkelingen in de moleculaire pathologie - therapie op maat” Masterclass voor Verpleegkundigen, Amersfoort, 10 april 2017 [www.oncowijs.nl/files/mamma-longcarcinoom/ 2017%20Schuring%20nieuwe %20anti%20tumor%20therapie.pdf]
  51. “Het nieuwe bevolkingsonderzoek naar baarmoederhalskanker”, het vernieuwd BVO voor doktersassistenten, voorlichting BVO-Noord, 21 Feb 2017, Treant, Bethesda
  52. “Predictive testing and monitoring treatment response in cancer patients by detection of circulating tumor DNA in cell free plasma, the UMCG experience”, Everest meeting, Vienna, 8th August 2017
  53. “ctDNA extraction methods”, IQNPath ctDNA Workshop “From Sample collection to clinical integration of the results - ensuring quality end to end”. Florence, 23rd June 2017 [http://www.iqnpath.org/wp-content/uploads/2015/09/Ed-Schuuring-ctDNA-extraction-methods-IQNPath-Florence-23062017-complete-v01.pdf]
  54. “ALK IHC vs ISH: case study”, Lung education series: “Fundamentals of Lung Cancer”, Ventana/Roche, Poundsbury, 1-2 December 2017 (invited panel speaker)
  55. “Panel discussion on lung cancer”, Lung education series: “Fundamentals of Lung Cancer”, Ventana/Roche, Poundsbury, 1-2 December 2017 (invited panel discussion)
  56. “NSCLC 2017”. MedTalks Oncology TV, Paneldiscussie in kader van Nascholing, Quadia, 7 december 2017, Hilversum [www.medtalks.nl/nascholing-nsclc-2017/] (invited TV debat)
  57. “Moleculaire Pathologie in Friesland: Liquid biopsy, Moleculaire Tumor Board, PATH-studie en CPTC”, FROHON vergadering, Tjongerschans, Friesland, 30 januari 2018 (invited speaker)
  58. “Moleculaire Diagnostiek in de longkanker pathologie”, IKNL Symposium Long “Moleculaire biologie/pathologie en oligometastasen”, regio-avond, Amersfoort, 5 maart 2018 (invited speaker)
  59. “ctDNA as a biomarker for early tumor response assessment in lung cancer patients treated with immunotherapy”. 2nd Cancer-ID ctDNA working group meeting, Wuppertal, 12-14 March 2018 (invited speaker)
  60. “Nieuwe anti-tumor therapie: ontwikkelingen in de moleculaire pathologie - therapie op maat” Masterclass voor Verpleegkundigen, Oncowijs, Amersfoort, 19 maart 2018 (invitated speaker)
  61. “Moleculaire Pathologie in de regio: HPV op indicatie en moleculaire diagnostiek van soliede tumoren”, 28 maart 2018, Treant, Bethesda, Hoogeveen (invited speaker)
  62. “Moleculaire Pathologie in de regio: HPV op indicatie en moleculaire diagnostiek van soliede tumoren”, 12 April 2018, Pathologie, Leeuwarden (invited speaker)
  63. “ctDNA as a biomarker for early tumor response assessment in lung cancer patients treated with immunotherapy”, Bio-Rad workshop at AACR 2018, 17th April 2018, Chicago (invited speaker)
  64. “ctDNA as a biomarker for early tumor response assessment in lung cancer patients treated with immunotherapy”. Cancer-ID 4th General Assembly Meeting. 2nd May 2018, Montpellier, France (invited speaker)
  65. “Het gebruik van circulerend tumor DNA in bloedplasma (“liquid biopsy”) om de respons op therapie van kankerpatiënten te monitoren”, Gast-college, Hanze Hogeschool Groningen, 31 mei 2018 (invited speaker)
  66. “Diverse DNA detectie methoden voor de predictie van respons op immunotherapie” tijdens de “Tweede Nederlandse cfDNA dag” (NVVP, NVKC), 14 juni 2018, Utrecht (invited speaker) [www.cfdna.nl/]
  67. ”Hunting for cancer cells and molecules in the blood”, Session “Advances in Lung Cancer Pathology and Management“,Maastricht Pathology 2018, 19th June 2018, Maastricht (invited speaker)
  68. ”ctDNA as a biomarker for early tumor response assessment in lung cancer patients treated with immunotherapy”, Two-Day Symposium for Molecular Biologists, Session „Immunotherapy Biomarkers“,30th ECP Bilbao, 10th September 2018, Bilbao (invited speaker)
  69. ”Molecular testing in thoracic oncology: problems, pitfalls and progress”, Joint Long Course Pulmonary Pathology, Thymic and Mediastinal Pathology and Molecular Pathology, session “Morphology and Genetics in Thoracic Pathology“, 30th ECP Bilbao, 11th September 2018, Bilbao (invited speaker)
  70. “ALK testing methods, guidelines and quality assessment” Roche symposium: “ALK positive lung cancers: latest clinical data and testing, guidelines for improved patient management, IAP meeting, Dead- See-Jordan, 17th October 2018 (invited speaker) [http://iap-ad.org/Documents/Archieve/Congress/2018/Lung2018/ ALK%20Testing%20Methods,%20Guidelines%20and%20Quality%20Assessment%20-%20Dr.%20Ed%20Schuuring.pdf]
  71. “Liquid biopsies: toepassingen, mogelijkheden en valkuilen”, UMCG KMBPio dag 2018, Pathologie, UMCG, 29 October 2018 (invited speaker)
  72. ”Nieuwe biomarkers uit bloed en supergevoelige methoden”, 11de avondsymposium: “Recente ontwikkeling in de moleculaire diagnostiek en behandeling van NSCLC, nu en in de nabije toekomst“, 31 oktober 2018, Groningen-Hoogkerk (invited speaker)
  73. “ctDNA as a biomarker for early tumor response assessment in lung cancer patients treated with immunotherapy”. Course „Translational Biomarkers in Immuno-Oncology: Liquid-Biopsy based biomarkers”,
  74. Cambridge Healthtech Institute’s. 3rd Annual World Preclinical Congress Europe. November 29-30, 2018, Sheraton Lisboa Hotel and Spa, Lisbon, Portugal (invited speaker)
  75. ”Stand van zaken MP in regio Noord: Predictieve moleculaire testing en Rol Moleculaire Tumor Board” Pathologie Friesland, Leeuwarden, 6 december 2018 (invited speaker)
  76. “Moleculaire Pathologie: historie, huidige diagnostiek, uitdagingen en nieuwe ontwikkelingen” BOP cursus: Moleculaire Pathologie, Papendaal, 19 – 20 december 2018 (speaker/organiser)
  77. “Liquid biopsies: Wat betekent dit voor de pathologie” BOP cursus: Moleculaire Pathologie, Papendaal, 19 – 20 december 2018 (speaker/organiser)
  78. “ctDNA as a biomarker for early tumor response assessment in lung cancer patients treated with immunotherapy”, Track 2: Emerging tools for immune response monitoring (BioRad-session), PMWC 2019 (Precision Medicine World Conference), Silicon Valley, 21st January 2019 (invited speaker) [www.pmwcintl.com/past/ed-schuuring-2019sv/]
  79. “Molecular testing in thoracic oncology: 2019 status in UMCG and Netherlands”, Side-visit at HQ BioRad Pleasanton CA, 25th January 2019 (invited visit)
  80. “Molecular testing in thoracic oncology: 2019 status in UMCG and Netherlands”, Side-visit at HQ Roche Pleasanton CA, 26th January 2019 (invited visit)
  81. “First experiences from the Dutch national hrHPV-population-based screening program”. Side-visit at HQ Roche Pleasanton CA, 26th January 2019 (invited visit)
  82. ”ALK IHC vs ISH” Ventana/Roche ALK-webinar “Battle of the ALKs: ALK IHC vs. ISH in treatment of ALK-positive advanced NSCLC”, recorded 28 February 2019 (invited speaker) [www.brighttalk.com/webcast/12161/351042]
  83. “ctDNA as a biomarker for early tumor response assessment in lung cancer patients treated with immunotherapy”. In session: “Exploring mechanisms of predictive and therapeutic response”. Cambridge HealthTech Institute‘s 4th Annual Immuno-Oncology Summit „Biomarkers for Immuno-Oncology“. March 18-19, 2019, London (invited speaker and session chair) [www.immuno-oncologyeurope.com/19]
  84. “Moleculaire Pathologie in regio Noord: Liquid biopsy, Moleculaire Tumor Board, PATH-studie”. Regionaal MD-overleg. MZH Groningen, 27 maart 2019
  85. “Ontwikkelingen in de moleculaire pathologie: therapie op maat”. Masterclass voor Verpleegkundigen “Nieuwe anti-tumor therapie”, Amersfoort,1 april 2019 (invited speaker)
  86. “Verzinnen, implementeren en borgen”. Symposium ter gelegenheid van afscheid van Jan Roodenburg ivm pensionering. Groningen 26 April 2019 (invited speaker)
  87. ”ALK IHC vs ISH” Ventana/Roche ALK-webinar “ALK IHC vs ISH and ALK Inhibitors in Treatment of ALK-Positive Advanced NSCLC”, recorded 29 April 2019 (invited speaker) [www.brighttalk.com/webcast/12161/357371]
  88. Panel Discussion-Prioritizing Testing in the Context of Predictive Markers, hosted by Dr. Paul A. Bunn Jr. Panel participants include Dr. Philippe Taniere, Dr. Erik Thunnissen, Prof Dr Ed Schuuring. Recorded May 2 2019 [www.brighttalk.com/webcast/12161/357673]
  89. Panel Discussion-Collaboration & Partnership between Oncologists & Pathologist, with Dr. Paul A. Bunn as your host. Panel participants include Prof Dr. Ed Schuuring, Prof Dr. Harry Groen and Dr. Corrado D'Arrigo. Recorded May 2 2019 [www.brighttalk.com/webcast/12161/357669]
  90. “Circulating Tumor DNA as a Molecular Bloodborne-Based: Biomarker to Predict Tumor Response in Lung Cancer Patients Treated with Immunotherapy”. In session: “Predictive and Prognostic Biomarker Discovery for Successful Therapy”. 7th International Molecular Diagnostics Europe. Cambridge HealthTech Institute‘s 2nd Annual „Biomarkers for Immunotherapy“. 6-9 May 2019, Lisbon, Portugal (invited speaker)
  91. “The role of Molecular Pathology in Precision Medicine: Challenges and Possibilities. Benelux Precision Medicine Forum. 13-14 May 2019, Utrecht (invited speaker)
  92. “Moleculaire Pathologie in regio Noord: Liquid biopsy, Moleculaire Tumor Board, PATH-studie” Gast-college, Hanze Hogeschool Groningen, 27 mei 2019 (invited speaker)
  93. “Kwaliteitsrondzending cfDNA in Europa: de resultaten” Derde Nederlandse cfDNA themadag 2019, NVVP/NVKC-dag, Utrecht, 21 Juni 2019 (invited speaker)
  94. “Implementatie Biomarkers in de praktijk” Netwerk-event Biomarkers en Diagnostiek (Health Holland), 1 juli 2019, Groningen (invited speaker)
  95. Joint session: Liquid-Biopsies: cell-free DNA. Joint Congress of Veterinary Pathology and Veterinary Clinical Pathology, 27 September 2019, Arnhem (invited speaker)
  96. “Primary hrHPV screening in the Dutch cervical cancer screening program”, European Meeting Molecular Diagnostics, Noordwijk aan Zee, 9-11 October 2019 (invited speaker)
  97. “Toepassing genen panels per deelspecialisme”. In: “Toepassingen van mutatieanalyse op FFPE-weefsel”. Eerste Regioavond Moleculaire Diagnostiek PNNN. Cyclus bij- & nascholing voor Pathologen & KMBP’ers door KMBP’ers. Leeuwarden, 16 Oktober 2019 (invited speaker)
  98. “Circulating tumor DNA as a molecular blood-borne biomarker to predict tumor response in lung cancer patients treated with immunotherapy”, In session: “Emerging Themes and Trends in Immuno-Oncology“, SelectBIO conference Immuno-Oncology Europe 2019, 28-29 October 2019, Rotterdam (invited speaker) [https://selectbiosciences.com/conferences/biographies.aspx?speaker=1688375&conf=IOEU2019]
  99. “Monitoring the effectiveness of lung cancer immunotherapies using droplet digital PCR”, In session: „Applications of digital PCR in oncology and infectious disease detection, diagnosis, monitoring and treatment“. SYNGEN Digital PCR Congress. 7-8 November 2019, London, UK (invited speaker and session chair)
  100. “NTRK testing: hoe vinden we de juiste patiënt ?” Roche meeting: “Oncologie Update 2019: Predictieve diagnostiek voor immuun- en doelgerichte therapie“, 13 November 2019, Rotterdam/Utrecht [https://oncologieupdate.com/pdfs/2.%20E.%20Schuuring.pdf]
  101. “NTRK diagnostiek in het lab”, In sessie: “Moleculaire Pathologie”, Pathologendag 2019. 21 November 2019, Arnhem (invited speaker) [https://pathology.nl/wp-content/uploads/2020/01/sessie-Moleculair-pres.-1-E.-Schuuring.pdf]
  102. “Molecular Pathology in the Netherlands”, In Track 1: “Molecular Diagnostics”, Genomics Live 2019, 4-5 December, Basel, Swiss (invited speaker and session chair)
  103. Circulating tumor DNA as a molecular blood-borne biomarker to predict tumor response in lung cancer patients treated with immunotherapy. Session „Immunoliquid Biopsy“. Simposium Liquid Biopsy 2020. 23-25 January 2020, Santiago de Compostela, Spain (invited speaker) [https://simposiobiopsialiquida.com/wp-content/uploads/2020/01/January-Friday-24th_Improving-the-protocols_Dr.Ed-Schuuring.pdf]
  104. “Implementatie PIK3CA testing in NL: Diagnostiek bij gemetastaseerde borstkanker. Wat is de huidige stand van zaken en hoe richten we de PIK3CA bepaling in in NL? Perspectief van de KMBPer” Novartis Pharma Advisory Board, 12 Februari 2020, Utrecht (invited speaker)
Last modified:01 March 2020 4.42 p.m.

Contact information

Antonius Deusinglaan 1
9713 AV Groningen
The Netherlands